

**AEROVATE THERAPEUTICS EMERGES FROM RA CAPITAL INCUBATOR WITH \$72.6 MILLION FUNDING FOR POTENTIAL DISEASE-MODIFYING PULMONARY ARTERIAL HYPERTENSION THERAPY**

***AV-101 is a Proprietary Inhaled Version of Imatinib, Which Has Proven Efficacy Treating PAH; Aerovate Was Founded and Seeded by RA Capital Management; Series A is Led by Sofinnova Investments; Includes New Investors Atlas Venture, Cormorant Asset Management, Surveyor Capital and Osage University Partners***

**BOSTON (August 6, 2020)** – Aerovate Therapeutics, Inc., has closed on \$72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). An oral version of imatinib showed significant efficacy in a phase 3 trial as a disease-modifying therapy for PAH, but it was poorly tolerated by PAH patients because of systemic side effects.

The Series A for Aerovate, which was founded and incubated by RA Capital Management, is led by Sofinnova Investments, a new investor in the company. Atlas Venture, Cormorant Asset Management, Surveyor Capital (a Citadel company) and Osage University Partners are the other new investors in the round.

“Aerovate is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. It is exciting to secure financing from such a strong syndicate to progress AV-101, our lead program,” said Aerovate founding President Benjamin Dake, PhD. He noted that the financing will take AV-101 through a clinical efficacy read-out, with a registrational trial scheduled to begin during the first half of 2021 with PAH patients. “Sufferers of PAH desperately need a disease-modifying therapy,” Dake added.

AV-101 is an easy-to-use, proprietary dry powder formulation of imatinib that delivers the medicine directly to the lungs. This approach should decrease the systemic adverse effects that hampered the oral version in PAH trials -- by reducing systemic exposure to the drug while simultaneously increasing the dose of medicine delivered directly to diseased lung tissues. AV-101 is administered with a simple inhaler, providing a convenient solution for patients compared to more cumbersome nebulized drugs currently approved in PAH. Those often require prolonged dosing protocols lasting many minutes, multiple times a day, including complicated device assembly and filling – likely reducing patient adherence and impacting real-world efficacy.

Aerovate emerged out of RA Capital’s seed and incubation program. The concept and proprietary drug product underlying AV-101 were co-invented by the RA Capital venture group and supported by its incubator, Carnot Pharma.

“With the support of the high caliber syndicate around the table, I believe Aerovate is poised to move this important treatment into the clinic immediately. This financing keeps the company on a rapid path towards offering this potentially transformational therapeutic to patients with

real need,” said RA Capital Managing Director and Aerovate Board Chair Joshua Resnick, MD. “AV-101 strives to provide PAH patients with the benefits of a disease modifying drug – in an easy-to-use format, free from the inconvenience of nebulized products – without the cancer-drug-like side effects of the oral version. This is extremely encouraging news for sufferers of this disease,” said Resnick.

“We are excited about AV-101’s potential because the core molecule, imatinib, has shown real efficacy for this use, including cases of hemodynamic remission in severely ill PAH patients. Aerovate’s team and their deep experience with PAH and aerosol development suggest that AV-101 may progress quickly and successfully through trials,” said Sofinnova General Partner and Aerovate Board Director Maha Katabi, PhD.

“Pulmonary arterial hypertension is a chronic disorder with a poor quality of life and five-year survival rate of only 57%. In multiple trials, imatinib showed strong clinical benefit for PAH patients that lasted for many months; they experienced improved exercise capacity, lower pulmonary vascular resistance, decreased pulmonary artery pressure and increased cardiac output. Imatinib addresses the underlying cause of the disease, unlike currently available vasodilator therapies,” said Aerovate Chief Medical Officer Hunter Gillies, MD. “Building on imatinib’s established efficacy, our research gives us strong confidence that AV-101, through targeted delivery to the lungs, will minimize systemic adverse effects, provide good tolerability and potentially be even better at treating the underlying disease than the oral version.”

“Given the significant unmet need in PAH, I am excited about leveraging my experience in developing novel products for underserved pulmonary diseases. Having successfully led the Esbriet team through approval for the treatment of IPF in the US, I look forward to working with Aerovate’s talented team to develop AV-101 to augment the current standard of care in PAH,” said Aerovate independent Board Director Jonathan Leff, MD.

The Aerovate board will include Atlas Venture Partner David Grayzel, MD, along with Dake, Katabi, Leff and Resnick.

## **About PAH**

PAH is a disorder that progresses rapidly and afflicts approximately 80,000 people worldwide and for which there are, to date, no approved disease-modifying therapies. PAH is a proliferative disorder of the pulmonary vasculature characterized by remodeling, constriction and occlusion of the small pulmonary arteries resulting in elevated blood pressure in the pulmonary circulation. PAH causes significant strain on the heart, leading to limited physical activity, heart failure and reduced life expectancy. Even with the current standard of care vasodilator therapies, which dilate pulmonary vessels but do not directly modify the disease, PAH often progresses at a fast pace. Aerovate estimates that, based on \$5 billion annual sales from the currently approved vasodilator drugs, the market for disease-modifying PAH therapies is significant.

## **About Aerovate Therapeutics**

Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's lead program is a potentially disease modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects. Aerovate was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences. For more information, please visit [www.aerovatetx.com](http://www.aerovatetx.com)

## **About RA Capital Management**

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, and diagnostics. For more information, please visit [www.racap.com](http://www.racap.com)

## **About Sofinnova Investments**

Sofinnova Investments is a biopharmaceutical investment firm with approximately \$2.2B in assets under management. Sofinnova invests in both private and public therapeutics-focused biotech companies, in both the U.S. and Europe, across all stages of company formation and growth seeking to build world class companies that aspire to dramatically improve the current state of medical care today and ultimately, the lives of patients. For more information, please visit [www.sofinnova.com](http://www.sofinnova.com)

Media Contact:

Michael-Jon Romano

Sommerfield Communications

[Michael-jon@sommerfield.com](mailto:Michael-jon@sommerfield.com)

+1 (212) 255-8386

## General Disclaimers

The information contained herein (the "Materials") is provided for informational and discussion purposes only and contains statements of opinion and belief. The Materials are not, and may not be relied on in any manner as, legal, tax, or investment advice. The Materials do not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor do they constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. and its affiliates and/or any investment products it advises (collectively, "RA Capital" or the "Firm"). Each recipient should make its own investigations and evaluations of RA Capital, and any investment products it advises, and should consult its own attorney, business adviser, and tax adviser as to legal, business, tax, and related matters thereto. The information contained in the Materials is not intended to be, and should not be viewed as, "investment advice" within the meaning of 29 C.F.R. §2510.3-21 or otherwise.

Any views expressed herein, unless otherwise indicated, are those of RA Capital as of the date indicated, are based on information available to RA Capital as of such date, and are subject to change, without notice, based on market and other conditions. No representation is made or assurance given that such views are correct and such views may have become unreliable for various reasons, including changes in market conditions or economic circumstances. Such views may have been formed based upon information, believed to be reliable, that was available at the time the Materials were published. Certain information contained herein concerning economic trends and/or data may be based on or derived from information provided by independent third-party sources. RA Capital believes that the sources from which such information has been obtained are reliable; however, it cannot guarantee the accuracy of such information and has not independently verified the accuracy or completeness of such information or the assumptions on which such information is based. RA Capital has no duty or obligation to update the information contained herein.

The content of the Materials neither constitutes investment advice nor offers any opinion with respect to the suitability of any security. Any references, either general or specific, to securities and/or issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, advice or recommendations to purchase, continue to hold, or sell such securities, or as an endorsement of any security or company. Certain current and prior investments may be highlighted in order to provide additional information regarding RA Capital's investment strategy, the types of investments it pursues, and current or anticipated exit strategies. In addition, due to confidentiality restrictions, the information contained herein might not reference investments in certain companies. Accounts managed by RA Capital may invest in certain companies referenced in the Materials; however, RA Capital makes no guarantees as to accuracy or completeness of views expressed in the Materials. Any strategies and companies referenced in the Materials may not be suitable for all investors.

As stated above, the Materials are not an offer or solicitation for the purchase or sale of any security, including any interest in RA Capital Healthcare Fund, L.P. (the "Master Fund") or RA Capital Healthcare International Fund Ltd. (the "Offshore Fund," and, collectively with the Master Fund, the "Fund"), and should not be construed as such. Such an offer will only be made by means of a confidential Private Placement Memorandum (the "PPM") to be furnished to qualified investors upon request. The information contained herein is qualified in its entirety by reference to the PPM, which contains additional information about the investment objective, terms, and conditions of an investment in the Fund, and also contains certain disclosures that are important to consider when making an investment decision regarding the Fund. In the case of any inconsistency between any information contained herein or in the Materials and the PPM, the terms of the PPM shall control.

The Materials are proprietary and confidential and may include commercially sensitive information. As such, the Materials must be kept strictly confidential and may not be copied or used for an improper purpose, reproduced, republished, or posted in whole or in part, in any form, without the prior written consent of RA Capital. The recipient of the Materials must not make any communication regarding the information

contained herein, including disclosing that the Materials have been provided to such recipient, to any person other than its authorized representatives assisting in considering the information contained herein. Each recipient agrees to the foregoing and to return (or destroy upon RA Capital's instructions) the Materials promptly upon request.

Any investment strategies discussed herein are speculative and involve a high degree of risk, including loss of capital. Investments in any products described herein and the Fund's performance can be volatile, and investors should have the financial ability and be willing to accept such risks. An investor could lose all or a substantial amount of his or her investment. The Fund may be leveraged. Interests in the Fund are illiquid, as there is no secondary market for the Fund interests, and none is expected to develop. The Fund interests are subject to restrictions on transfer. Prior to investing in the Fund, investors should read the PPM and pay particular attention to the risk factors contained therein. Fees and expenses charged in connection with an investment in the Fund may be higher than the fees and expenses of other investment alternatives and may offset investment profits of the Fund. RA Capital has total trading authority over the Fund. The use of a single advisor applying generally similar trading programs could mean lack of diversification and, consequentially, higher risk. A portion of the trades executed for the Fund may take place on foreign exchanges. It should not be assumed, and no representation is made, that past investment performance is reflective of future results. Nothing herein should be deemed to be a prediction or projection of future performance. To the extent any prior or existing investments are described, RA Capital makes no representations, and it should not be assumed, that past investment selection is necessarily reflective of future investment selection, that any performance discussed herein will be achieved or that similar investment opportunities will be available in the future or, if made, will achieve similar results.

In particular, to the extent valuation information is provided for any unrealized investments, such valuations are RA Capital's estimates as of the date set forth in the Materials, and there can be no assurance that unrealized investments will be realized at such valuations. While RA Capital believes any valuations presented herein are reasonable, such valuations may be highly subjective, particularly for private investments, and are based on information provided by third parties and/or RA Capital's assumptions, any or all of which might be mistaken or incomplete. Actual realized returns will depend on, among other factors, future operating results, the value of the assets and market conditions at the time of disposition, any related transaction costs, and the timing and manner of sale. All of which may differ from the assumptions on which the valuations contained herein are based. As a result of the foregoing, actual realized returns may differ materially from the valuations contained herein.

Certain information contained in this document constitutes "forward-looking statements," which can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "target," "project," "estimate," "intend," "continue," or "believe," or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, actual events or results or the actual performance of any investment may differ from those reflected or contemplated in such forward-looking statements. Prospective investors should not rely on these forward-looking statements when making an investment decision.

None of the information contained herein has been filed with the U.S. Securities and Exchange Commission, any securities administrator under any securities laws of any U.S. or non-U.S. jurisdiction, or any other U.S. or non-U.S. governmental or self-regulatory authority. No such governmental or self-regulatory authority will pass on the merits of any offering of interests by RA Capital or the adequacy of the information contained herein. Any representation to the contrary is unlawful. The interests in the Fund have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended, or qualified or registered under any applicable state, local, provincial, or other statutes, rules, or regulations. The Fund has not been, and will not be, registered as an investment company under the U.S. Investment Company Act of 1940, as amended.